In the Media
Lentigen Technology Inc., a Miltenyi Biotec Company, Acquires University of Maryland, Baltimore CAR-T Cell Start-Up, Living Pharma, Inc.
Posted on: Thursday, July 20, 2017
Lentigen Technology Inc., a leading provider of GMP lentiviral vectors, will further advance Living Pharma’s personalized chimeric antigen receptor (CAR) T-cell therapies targeting various cancers.
» Read moreLiving Pharma Adds Noted Oncologist to its Advisory Board
Posted on: Tuesday, November 1, 2016
Living Pharma, Inc. announced today that it has added Aaron P. Rapoport, MD, to its advisory board.
» Read moreLiving Pharma Adds Venture Capital Executive to its Advisory Board
Posted on: Wednesday, June 1, 2016
Living Pharma, Inc. announced today that it has added Isai Peimer, PhD, to its advisory board.
» Read moreLiving Pharma Signs Exclusive License Agreement with UMB for a Novel Universal CAR T Cell Platform Technology
Posted on: Thursday, January 28, 2016
Living Pharma, Inc. announced today that it has entered into an exclusive license agreement with the University of Maryland, Baltimore (UMB) to develop Anti-Tag Chimeric Antigen Receptor (AT-CAR™) engineered T cell therapy.
» Read more